Skip to main content
. Author manuscript; available in PMC: 2023 Jun 18.
Published in final edited form as: Surg Oncol Clin N Am. 2022 Oct;31(4):569–579. doi: 10.1016/j.soc.2022.06.001

Fig. 1.

Fig. 1.

Patient with left breast multicentric left breast ER-negative, progesterone receptor-negative, HER 2-positive IDC. (A) shows dynamic contrast-enhanced MRI showing extensive mass and nonmass enhancement in outer left breast. In (B), 18F-FES PET scan shows no uptake in left breast, consistent with ER negativity of known tumor, with expected uptake in liver and gastrointestinal tract.